Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.20)
# 2,820
Out of 5,139 analysts
39
Total ratings
47.22%
Success rate
-2.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $16.71 | +115.50% | 1 | Dec 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $89 → $94 | $91.05 | +3.24% | 4 | Dec 9, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $46.51 | +108.56% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $16.80 | +138.10% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $33.33 | +95.02% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $800.01 | +13.75% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.53 | +815.03% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $214.35 | +3.57% | 5 | Sep 22, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $1.65 | +203.03% | 1 | Apr 29, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.20 | +172.73% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $21.13 | +704.54% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $6.02 | +232.23% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $285.04 | -27.73% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.62 | +739.69% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.23 | +348.43% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $72.27 | -16.98% | 1 | Oct 5, 2022 |
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $16.71
Upside: +115.50%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $89 → $94
Current: $91.05
Upside: +3.24%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $46.51
Upside: +108.56%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $16.80
Upside: +138.10%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $33.33
Upside: +95.02%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $800.01
Upside: +13.75%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.53
Upside: +815.03%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $214.35
Upside: +3.57%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.65
Upside: +203.03%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.20
Upside: +172.73%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $21.13
Upside: +704.54%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $6.02
Upside: +232.23%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $285.04
Upside: -27.73%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.62
Upside: +739.69%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.23
Upside: +348.43%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $72.27
Upside: -16.98%